Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Dexmedetomidine in Patients With Agitated Delirium in Palliative Care: an Open-label Phase 1/2 Proof-of-concept, Feasibility, and Dose-finding Clinical Trial

NCT04824144 is registered in ClinicalTrials.gov with Bruyère Health Research Institute. as lead sponsor.

NCT NCT04824144
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04824144 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Dexmedetomidine in Patients With Agitated Delirium in Palliative Care: an Open-label Phase 1/2 Proof-of-concept, Feasibility, and Dose-finding Clinical Trial
Lead sponsor
Bruyère Health Research Institute.
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 30, 2024
Completion date
March 31, 2026
Enrollment
50 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

delirium of mixed origin, hyperactive delirium